Concord Biosciences was established in 1986 and over the past 27 years has built a rich tradition and culture by serving clients with scientific excellence and innovative services. The Company delivers outstanding value and service guided by a seasoned leadership team that starts with an entrepreneurial Board of Directors with widespread healthcare experience, a Chief Executive Officer with extensive experience and knowledge of the industry and an executive management team with deep industry related experience across the Company’s three key service areas — Drug Safety & Metabolism, Bioanalytical, and Agrochemicals. The Company supports the outstanding delivery of science and service through an experienced team of associates with a dedicated pursuit of meeting customers’ needs and a relentless striving towards operational excellence in everything they do.

Clifford W. Croley
Chief Executive Officer

Mr. Clifford W. Croley serves as the Chief Executive Officer at Concord Biosciences LLC and is responsible for providing strategic and operational hands–on leadership for the company. He has previously worked professionally to revive over 100 privately held underperforming companies and has participated at the Board level (as both a Board Member and Board Special Advisor) in numerous situations. Clifford has served as the Chief Executive Officer for many companies across a diverse range of industries including healthcare, construction, distribution, and automotive manufacturing. He is a business and community leader and currently sits on the boards of multiple middle–market companies. Clifford has invested in a number of middle market businesses over the last two decades both individually and in partnership with well–known private equity firms.

Clifford has achieved a B.S. and M.S and M.B.A. degree.

Farhad Sayyarpour, Ph.D.
Director, Bioanalytics, Agrochemical Product Development

Farhad has over twenty years of analytical/bioanalytical chemistry experience in the US pharmaceutical and Contract Research Organizations. He has broad analytical, bioanalytical and quality experience which includes extensive development and deployment of operational and quality compliance systems for research and development, and laboratory testing facilities. He is an expert in small molecule and peptides method development and analysis via a variety of analytical instruments. Farhad is a leader in establishing turn arounds in laboratories by positively influencing colleagues and stakeholders resulting in compliance with quality systems and regulatory requirements. He excels at building cross functional teams, and customer and global relationships, thru management of strategy, vision, execution and measurement. Farhad received his BSc. From Austin Peay State University and his Ph.D. from the University of Memphis.

Connie Collins, RVT, RLATG
Director of Operations

Ms. Connie Collins is a laboratory animal professional with over 15 years’ experience in veterinary medicine, drug development, and harmonization of regulatory agencies concerned with animal welfare and compliance. Ms. Collins is Director of Operations and runs the daily operations of Concord’s Drug, Safety & Metabolism (DSM) group. In addition to operational duties, Ms. Collins chairs Concord’s Institutional Animal Care and Use Committee (IACUC), As Director of Operations for DSM, she routinely provides directional oversight of the technical and support staff while overseeing the implementation of the proposal in accordance with signed projects. Ms. Collins regularly ensures that resources are properly allocated to meet study and schedule requirements. Furthermore, she maintains and updates financial forecasting, divisional profitability, and study progress to enable accurate financial tracking while collaborating with business development teams and fostering client–relationships. Ms. Collins facilitates all animal welfare agency inspections and serves as primary contact for USDA, OLAW and AAALAC. Ms. Collins is a Registered Veterinary Technician in the State of Ohio and a Registered Laboratory Animal Technologist with the American Association of Laboratory Animal Science.

Roger Hawks, Ph.D., DABT
Director of Toxicology

Dr. Roger Hawks has over 20 years of experience in the fields of pharmacology and toxicology. In addition to supervising the senior scientists and day–to–day scientific aspects of Concord’s Drug Safety & Metabolism (DSM) group, Dr. Hawks also is Study Director on complicated studies. Dr. Hawks’ primary role is to design, initiate, monitor, and interpret/report results for Good Laboratory Practice (GLP) and non–GLP studies to evaluate the potential toxicity of chemicals and pharmaceuticals. He routinely directs and oversees staff conducting toxicology and pharmacology studies while regularly communicating study progress with clients. As Manager of the Study Director group of DSM, Dr. Hawks is responsible for review of protocols and reports generated by other study directors, providing scientific and technical review of prospective proposals for research, and assisting in the development of in–house training programs for the technical staff. Prior to joining Concord, Roger was employed by BASi and XOMA Corporation as a Study Director/Scientist, and also was employed by BASF Corporation and the U.S. Environmental Protection Agency (Office of Pesticide Programs) as a Toxicologist. Dr. Hawks received his Ph.D. and Masters of Science from the University of Rochester in 1997.